Literature DB >> 7726191

Musculoskeletal manifestations of Lyme disease.

A C Steere1.   

Abstract

Musculoskeletal involvement, particularly arthritis, is a common feature of Lyme disease. Early in the illness, patients may experience migratory musculoskeletal pain in joints, bursae, tendons, muscle, or bone in one or a few locations at a time, frequently lasting only hours or days in a given location. Weeks to months later, after the development of a marked cellular and humoral immune response to the spirochete, untreated patients often have intermittent or chronic monoarticular or oligoarticular arthritis-primarily in large joints, especially the knee-during a period of several years. The diagnosis of Lyme arthritis is usually based on the presence of this characteristic clinical picture, exposure in an endemic area, and an elevated immunoglobulin G antibody response to Borrelia burgdorferi. In addition, spirochetal DNA can often be detected in joint fluid by polymerase chain reaction. Lyme arthritis can usually be treated successfully with 1-month courses of oral doxycycline or amoxicillin or with 2- to 4-week courses of intravenous ceftriaxone. However, patients with certain genetic and immune markers may have persistent arthritis, despite treatment with oral or intravenous antibiotics. B. burgdorferi may occasionally trigger fibromyalgia, a chronic pain syndrome with diffuse joint and muscle symptoms. This syndrome does not appear to respond to antibiotic therapy.

Entities:  

Mesh:

Year:  1995        PMID: 7726191     DOI: 10.1016/s0002-9343(99)80043-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  Cloning and molecular characterization of plasmid-encoded antigens of Borrelia burgdorferi.

Authors:  J T Skare; D M Foley; S R Hernandez; D C Moore; D R Blanco; J N Miller; M A Lovett
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Induction of pro- and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is mediated by CD14.

Authors:  G H Giambartolomei; V A Dennis; B L Lasater; M T Philipp
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 3.  Assessment, investigation, and management of acute monoarthritis.

Authors:  S H Till; M L Snaith
Journal:  J Accid Emerg Med       Date:  1999-09

4.  VraA (BBI16) protein of Borrelia burgdorferi is a surface-exposed antigen with a repetitive motif that confers partial protection against experimental Lyme borreliosis.

Authors:  M Labandeira-Rey; E A Baker; J T Skare
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Sudeck's atrophy in Lyme borreliosis.

Authors:  H R Bruckbauer; V Preac Mursic; P Herzer; H Hofmann
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

6.  Borrelia burgdorferi migrates into joint capsules and causes an up-regulation of interleukin-8 in synovial membranes of dogs experimentally infected with ticks.

Authors:  R K Straubinger; A F Straubinger; L Härter; R H Jacobson; Y F Chang; B A Summers; H N Erb; M J Appel
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

7.  A short-term Borrelia burgdorferi infection model identifies tissue tropisms and bloodstream survival conferred by adhesion proteins.

Authors:  Jennifer A Caine; Jenifer Coburn
Journal:  Infect Immun       Date:  2015-05-26       Impact factor: 3.441

8.  Detection and molecular typing of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks and in different patient samples from southwest Germany.

Authors:  D Schaarschmidt; R Oehme; P Kimmig; R D Hesch; S Englisch
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

9.  Detection and typing of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks attached to human skin by PCR.

Authors:  G Liebisch; B Sohns; W Bautsch
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

10.  Local production of IFN-gamma by invariant NKT cells modulates acute Lyme carditis.

Authors:  Chris M Olson; Tonya C Bates; Hooman Izadi; Justin D Radolf; Sally A Huber; Jonathan E Boyson; Juan Anguita
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.